Plasma Fractionation Market Overview

The Global Plasma Fractionation Market is witnessing steady expansion, driven by rising demand for plasma-derived therapies, increasing awareness about rare and chronic diseases, and advancements in healthcare infrastructure across developing economies. Valued at USD 34.4 billion in 2025, the market is forecasted to reach USD 55.3 billion by 2033, growing at a CAGR of 6.4% over the forecast period.

Plasma fractionation is an important process in biotech that helps extract and purify key proteins from human blood plasma. It focuses on gathering immunoglobulins, albumin, clotting factors, and other vital components. These are used to treat serious conditions like hemophilia, immune deficiencies, and autoimmune diseases. Increased investments in plasma centers, greater awareness of plasma-based treatments, and support from governments and healthcare providers boost the industry. As demand for immunoglobulin therapies rises, especially for immune deficiencies and nerve disorders like CIDP and Guillain-Barré Syndrome, the need for larger plasma processing facilities grows. Market trends show a shift toward better technology for plasma separation and purification, making production safer and more efficient. Companies are building more plasma collection sites around the world to meet higher demand.

Plasma Fractionation Market Drivers and Opportunities

The rising prevalence of immunodeficiency and chronic diseases is anticipated to lift the plasma fractionation market during the forecast period

The growth of the global plasma fractionation market is mainly driven by more cases of primary immunodeficiency and long-term illnesses like hemophilia, CIDP, and hereditary angioedema. These health problems need ongoing treatment with plasma-based products such as immunoglobulins, albumin, and clotting factors. As testing methods improve and awareness increases among doctors and patients, diagnosing and treating these conditions has become more common. Immunoglobulins are especially needed for treating many immune system issues, including both inherited and acquired immunodeficiencies. The rise of autoimmune and inflammatory diseases around the world has also boosted demand. Chronic liver problems, injuries, and surgeries often require albumin-based therapies, adding to market growth. The growing number of these diseases, along with an aging population more likely to face such health issues, means there is a steady need for plasma-derived treatments. Healthcare providers are beginning to see that catching these conditions early and treating them can save costs and improve outcomes. This has led to broader insurance coverage, easier access to therapies, and consistent demand. All these factors are helping the plasma fractionation market grow worldwide.

Favorable government policies and increasing healthcare expenditure drive the global plasma fractionation market

Supportive government policies and increasing healthcare spending around the world are helping the growth of the global plasma fractionation industry. Both developed and developing countries are starting to see how useful plasma-derived medicines are. They are working to make sure these treatments are safe, available, and affordable. Countries are creating blood policies, partnering with private companies, and building local plasma fractionation plants. This is especially true in nations that want to cut down on imports. Clearer rules for approving products and maintaining quality are also making plasma therapies easier to access. In Europe and other countries with strong health systems, plasma products are often covered by insurance, helping more people get treatment. In poorer countries, rising incomes and better health coverage are making life-saving therapies available to more people. Spending more on vaccination programs and disease control also helps expand the use of immunoglobulins and clotting factors. These efforts are closing the gap in treatment access in many regions. They also encourage companies to grow and invest in new research and production. As a result, the worldwide market for plasma products continues to expand over the long term.

Opportunity for the Plasma Fractionation Market

Increasing R&D in novel plasma-derived therapies is a significant opportunity in the global plasma fractionation market

The growing focus on research and development for novel plasma-derived therapies offers significant long-term growth potential in the global market. While traditional products like immunoglobulins, albumin, and clotting factors continue to dominate, the future lies in expanding the therapeutic applications of plasma proteins and discovering new plasma components with clinical utility. Ongoing studies are exploring the use of plasma-derived biologics in neurological disorders, oncology, sepsis management, and rare genetic diseases. Advanced research is also focused on recombinant versions and hybrid therapies that can complement or enhance existing plasma-based treatments. In addition, growing interest in individualized medicine and biologic drug innovation is pushing companies to invest in more targeted and disease-specific plasma fractions. The use of big data, biobanking, and proteomics is enhancing the understanding of plasma protein functions and their roles in complex disease pathways. These developments are not only expanding the pipeline of therapeutic options but also allowing companies to differentiate themselves in an increasingly competitive landscape. With strong R&D capabilities, favorable funding environments, and increasing patient demand for effective biologics, innovation in plasma-derived therapies is poised to open new avenues for market expansion and clinical breakthroughs.

Plasma Fractionation Market Scope

Plasma Fractionation Market Report Segmentation Analysis

The global Plasma Fractionation industry analysis is segmented by Product, by Application, by End-user, and by region.

The Immunoglobulin segment accounted for the largest market share in the global Plasma Fractionation market

By Product, the market divides into segments such as Albumin, Immunoglobulin, Coagulation Factors, Protease Inhibitors, and Others. The Immunoglobulin segment leads the global plasma fractionation market. These immunoglobulins are essential in treating primary and secondary immunodeficiency diseases, autoimmune disorders, and neurological conditions like CIDP and Guillain-Barré syndrome. The segment’s large share is driven by the rising number of these conditions worldwide and the increased off-label use of immunoglobulins. Growing awareness, better diagnosis, and expanded uses in immunology and neurology also boost demand. The importance of immunoglobulins in therapy, along with ongoing advances in purification and manufacturing, keeps this segment at the forefront of the market.

The Immunology & Neurology segment holds a major share in the Plasma Fractionation market

By Application, the market is broken into Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others. The Immunology & Neurology segment holds the largest share. It grows due to the widespread use of plasma-based products, especially immunoglobulins, for autoimmune, immune deficiency, and neurological diseases. As these conditions become more common worldwide and treatment needs increase, demand in this area rises. Developments in neurological testing, more clinical trials in immune therapies, and more investment in specialized care have reinforced this segment’s strong position. It remains the biggest application area for plasma fractionation products.

The Hospitals & Clinics segment dominates in the Plasma Fractionation market

By End-User, the market is split into Hospitals & Clinics, Clinical Research Labs, and Others. Hospitals and clinics make up the largest share. These healthcare facilities are the main outlets for plasma-based therapies used in severe and long-term conditions. They see more patients, offer specialized care, and have ready access to plasma products. Growth in hospital infrastructure, especially in rising economies, and the preference for hospital-based treatments and surgeries support this dominance. These institutions play a vital role in diagnosis, emergency treatment, and ongoing care, helping them stay at the top.

The following segments are part of an in-depth analysis of the global Plasma Fractionation Market:

Plasma Fractionation Market Share Analysis by Region

The North America region is projected to hold the largest share of the global Plasma Fractionation market over the forecast period.

North America held the largest share of the global plasma fractionation market, with 44.2% in 2025. It remains the leader because of its advanced healthcare systems, widespread awareness of plasma therapies, and the presence of major industry players. The region has a strong network for plasma collection, strict rules from agencies like the U.S. FDA, and significant investments from both government and private sectors in biopharmaceuticals. The rise in autoimmune and immune deficiency diseases, along with an aging population, has pushed up demand for therapies like immunoglobulins and albumin. Supportive reimbursement policies, high healthcare spending, and ongoing research also fuel growth. North America’s ability to export products and develop new technologies for plasma purification gives it a clear edge in the global market.

Meanwhile, the Asia Pacific region is expected to see the fastest growth rates over the coming years. Countries like China, India, and Japan are experiencing more health spending, rising awareness among patients, better access to care, and increased need for plasma-based medicines. These factors are expected to drive the market’s expansion in the region.

Plasma Fractionation Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of products. Some of the key players are Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin, Bio Products Laboratory Ltd., and Intas Pharmaceuticals Ltd.

Global Plasma Fractionation Market Recent Developments News:

• In July 2024, Biotest AG has agreed with Kedrion to fully commercialize and distribute its immunoglobulin therapy, Yimmugo, in the U.S. market. This follows the recent FDA approval of Yimmugo under a Biologics License Application (BLA), marking a significant milestone for the company's expansion in the U.S.
• In January 2024, Takeda secured FDA approval for its Immune Globulin Infusion 10% solution as an intravenous treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The therapy is designed to reduce neuromuscular disability and impairment, offering a new treatment option for patients with this rare neurological condition.

The Global Plasma Fractionation Market is dominated by a few large companies, such as

●        Grifols S.A.

●        CSL Limited

●        Takeda Pharmaceutical Company Limited

●        Octapharma AG

●        Kedrion S.p.A

●        LFB S.A.

●        Biotest AG

●        Sanquin

●        Bio Products Laboratory Ltd.

●        Intas Pharmaceuticals Ltd

●        Other Prominent Players